E2A-PBX1 exhibited a promising prognosis in pediatric acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol
White blood cell
Minimal Residual Disease
Clinical endpoint
DOI:
10.2147/ott.s115257
Publication Date:
2016-11-23T01:12:34Z
AUTHORS (13)
ABSTRACT
The objective of this study was to observe the prognosis pediatric patients with E2A-PBX1-positive acute lymphoblastic leukemia (ALL) from treatment CCLG-ALL2008 protocol.Three hundred and forty-nine Chinese pre-B-cell ALL were enrolled in December 2008 September 2013. Of these, 20 E2A-PBX1 expression 223 without gene stratified into two cohorts. Clinical biological characteristics 5-year event-free survival (EFS), relapse-free (RFS), overall (OS) analyzed compared between these groups.The fusion transcript detected 349 (5.7%) patients. Compared gene-negative subgroup, younger age but did not show significant differences white blood cell (WBC) count or gender distribution at primary diagnosis. Moreover, there more inferior karyotypes subgroup (P=0.035). With protocol, showed a favorable response lower minimal residual disease (MRD) levels (<10-4) time point 1 (TP1, P=0.039) no superior steroid histological remission. We also observed promising outcome, EFS reaching 95.0%±4.9% versus 66.3%±3.9% group (P=0.039). However, we find RFS (P=0.061) OS (P=0.113).Our data provided clinical observation Patients benefited well risk-based intensified trial, MRD longer duration though they had
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....